pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Taiho Oncology Inc

updated 5mo ago
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval6 co-mentions · 3 sources
  • drugfutibatinib6 co-mentions · 3 sources
  • drugLYTGOBI6 co-mentions · 3 sources
  • tagOncology3 co-mentions · 3 sources
  • tagSmall Molecule3 co-mentions · 3 sources
pipeline
5
marketed
2
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Phase 1: 1Phase 3: 1Marketed: 2Unknown: 1
1Phase 11Phase 32Marketed1Unknown
Marketed
(tipiracil hydrochloride + trifluridine)
Adenocarcinoma Of The Gastroesophageal Junction
Marketed
futibatinib
Bile Duct Cancer (Cholangiocarcinoma)
Fibroblast growth factor receptor
Phase 3
(azacitidine + cedazuridine)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Phase 1
TAS-2940
Solid Tumor
drug
LYTGOBI

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Taiho Oncology Inc jobs →

News

  • Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
    When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.
    biospace · 6d ago
  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 9d ago
  • ArriVent collapses on disappointing lung cancer data
    More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.
    biopharma_dive · 1mo ago
  • Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefit
    Analysts believe Cullinan Therapeutics and Taiho Oncology can overcome the safety risks as zipalertinib “sets [a] new bar” for first-line treatment of a type of lung cancer. The candidate is alread…
    biospace · 2mo ago
  • Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
    Cullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the f…
    fiercebiotech · 2mo ago
  • New Taiho, Cullinan data heats up lung cancer drug battle
    The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
    biopharma_dive · 3mo ago
  • Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
    Taiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.
    biospace · 3mo ago
  • Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
    Taiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer.…
    endpoints · 3mo ago
  • FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
    The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.
    onclive · 6mo ago
view all news mentions →
identifiers
source
globaldata
top tags
Oncology4
mentioned in
9news items
entity-linker matched
Data sources
openFDA
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?